Scottish biopharmaceutical firm, Antibody Analytics, has been making a huge effort in supporting drug development throughout the COVID-19 pandemic.
The biotech team, which specialises in creating methods to support drug developers in treating diseases such as cancer, have been helping to create new drugs, along with repurposing existing ones.
The lab, which is still open to carry out key work, has created a mock virus that behaves in a similar way to COVID-19, allowing scientists to experiment how certain medicines react against the virus, and test new drug designs.
"By developing these experimental systems, we are in a position to support those working to combat the virus. Our team are working very hard in ensuring that no stone is left unturned, with the hope that a cure can be found."Andy Upsall, Managing Director
How we did it.
We recently provided £500k to help support the rapid growth of the company, expanding its lab space and recruiting top scientists from around the world. Antibody Analytics operate in an industry where innovative thinking and design are a necessity. They needed a partner who understood their business and its funding requirements. Our patient capital, multi-stage funding and flexibility on exit fulfilled their needs.
The company also needed general business support and we’ve been there to help signpost and act as a sounding board. They’re growing from a strong base and making a real difference to our local and national community.
Striving for a cure
Providing huge support to those fighting Covid-19 by providing the ability to test new drugs that are being developed.